Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT06068959 |
Other study ID # |
220824a |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
February 29, 2024 |
Est. completion date |
August 10, 2024 |
Study information
Verified date |
September 2023 |
Source |
University of Nove de Julho |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
These studies aim to validate the effects of photobiomodulation using clusters of 850nm LEDs
(infrared) and 630nm LEDs (red); in pain and cervical and mandibular mobility in patients
with TMD. It is a randomized, controlled, and blind clinical trial, which will consist of n=
36, of both genders, with ages ranging from 18 to 45 years, divided into 2 groups: Group 1
Red and infrared LED cluster, Group 2 placebo. The areas where they will receive
photobiomodulation will be the TMJ area, masseter muscles, temporal muscles, scalenes, and
trapezius. 6 non-consecutive sessions will be performed over 2 weeks. Diagnostic Criteria for
Temporomandibular Disorders - DC/TMD will be used to determine TMD and validate participants.
To validate the mandibular range of motion (ADM) a pachymeter will be used and for the
cervical ADM a goniometer (fleximeter). The pain will be validated using the visual analog
scale-VAS. All participants will be evaluated after the first therapeutic intervention, and
again at the end, following the same validation procedures used initially.
Description:
The term temporomandibular disorders (TMD), according to the American American Dental
Association (ADA), refers to a group of disorders characterized by pain in the
temporomandibular joint (TMD) in the periauricular area or in the masticatory muscles, in
addition to TMD sounds during jaw function and deviation or restriction of jaw movements. Its
multifactorial etiology is related to a heterogeneous group of functional, structural, and
psychological factors, making it difficult to identify the association between a single
etiological factor and the signs and symptoms of TMD. As a treatment option, it
hasphotobiomodulation, using different light sources, alone or in combination. These studies
aim to validate the effects of photobiomodulation using clusters of 850nm LEDs (infrared) and
630nm LEDs (red); in pain and cervical and mandibular mobility in patients with TMD. It is a
randomized, controlled, and blind clinical trial, which will consist of n= 36, of both
genders, with ages ranging from 18 to 45 years, divided into 2 groups: Group 1 Red and
infrared LED cluster, Group 2 placebo. The areas where they will receive photobiomodulation
will be the TMJ area, masseter muscles, temporal muscles, scalenes, and trapezius. 6
non-consecutive sessions will be performed over 2 weeks. Diagnostic Criteria for
Temporomandibular Disorders - DC/TMD will be used to determine TMD and validate participants.
To validate the mandibular range of motion (ADM) a pachymeter will be used and for the
cervical ADM a goniometer (fleximeter). The pain will be validated using the visual analog
scale-VAS. All participants will be evaluated after the first therapeutic intervention, and
again at the end, following the same validation procedures used initially.